| | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | 28/01/23 13:09 | Company Update |  |
| | Earnings Call for Quarter - III, FY 2023 scheduled to be held on Friday, February 10, 2023, at 16.00 hrs (IST). | |
| |
| | Board Meeting Intimation for Considering And Taking On Record Unaudited Financial Results Of The Company For The Quarter And Nine-Months Ended December 31, 2022. | 25/01/23 10:11 | Board Meeting | |
| | LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2023 ,inter alia, to consider and approve unaudited financial results of the Company for the quarter and nine-months ended December 31, 2022. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 24/01/23 12:37 | Company Update | |
| | Lupin Launches LYFE, its Digital Therapeutic Solution for Holistic Heart Care. | |
| |
| | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | 20/01/23 11:47 | Company Update | |
| | Disclosure pursuant to allotment of 114899 shares under ESOP. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 18/01/23 14:26 | Company Update | |
| | Lupin Launches Sacubitril and Valsartan Combination Drug for
Heart Failure Patients. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 16/01/23 13:23 | Company Update | |
| | Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets. | |
| |
| | U.S. FDA Inspection Of The Company'S Somerset Manufacturing Facility. | 15/01/23 21:14 | Company Update | |
| | U.S. FDA Inspection of the Company's Somerset manufacturing facility. | |
| |
| | U.S. FDA Inspection Of The Company'S Nagpur Unit-2 Injectable Manufacturing Facility. | 30/10/22 12:30 | Company Update | |
| | U.S. FDA Inspection of the Company's Nagpur Unit-2 injectable manufacturing facility. | |
| |
| | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | 28/10/22 14:47 | Company Update | |
| | Earnings Call for Quarter - II, FY 2023 is scheduled on Thursday, November 10, 2022 at 16.00 hrs (IST). | |
| |
| | Board Meeting Intimation for Considering And Taking On Record The Unaudited Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2022 And Other Business Matters. | 27/10/22 10:25 | Board Meeting | |
| | LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2022 ,inter alia, to consider and approve the unaudited financial results of the Company for the quarter
and half year ended September 30, 2022 and other business matters. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 20/10/22 13:13 | Company Update | |
| | Lupin Launches Paliperidone Extended-Release Tablets in the United States. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 20/10/22 07:40 | Company Update | |
| | Lupin Signs Agreement to Acquire Two Inhalation Brands from Sunovion. | |
| |
| | Update On The Company'S Biotech Manufacturing Facility. | 19/10/22 22:14 | Company Update | |
| | Update on the Company's Biotech manufacturing facility. | |
| |
| | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate | 19/10/22 14:11 | | |
| | Intimation regarding loss of Share Certificates by Shareholder. | |
| |
| | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | 13/10/22 14:42 | Company Update | |
| | Disclosure pursuant to allotment of 17306 shares under ESOP. | |
| |
| | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate | 13/10/22 14:20 | | |
| | Intimation of Loss of Share Certificate by Shareholder. | |
| |
| | Announcement under Regulation 30 (LODR)-Cessation | 07/10/22 19:21 | Company Update | |
| | Dr. Kamal K. Sharma (DIN: 00209430), Non-Executive Vice Chairman of the Company, will be stepping down from the Board of Directors of the Company with effect from October 14, 2022. | |
| |
| | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate | 07/10/22 14:40 | | |
| | Intimation of Loss of Share Certificate by Shareholder. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 07/10/22 11:49 | Company Update | |
| | Lupin Partners with Global Agencies to Increase Patient Access to Tuberculosis Prevention Treatment. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 06/10/22 22:10 | Company Update | |
| | Lupin Appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer. | |
| |
| | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate | 04/10/22 14:22 | | |
| | Intimation of Loss of Share Certificate by Shareholder. | |
| |
| | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | 04/10/22 12:27 | Company Update | |
| | Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2022. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 04/10/22 12:17 | Company Update | |
| | Lupin Receives Approval from U.S. FDA for Darunavir Tablets. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 01/10/22 16:12 | Company Update | |
| | Lupin Life announces association with Vikram Vedha as official energy partner with its Be One health and wellness supplement. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 01/10/22 16:06 | Company Update | |
| | Lupin gets EIR from U.S. FDA for its Ankleshwar Manufacturing Facility. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 29/09/22 15:32 | Company Update | |
| | Lupin Receives Approval from U.S. FDA for Mirabegron Extended-Release Tablets. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 29/09/22 14:01 | Company Update | |
| | Lupin Launches Sildenafil for Oral Suspension in the United States. | |
| |
| | Communication From U.S. FDA Regarding The Company'S Tarapur, Maharashtra (India) Facility. | 29/09/22 10:29 | Company Update | |
| | Company has received a warning letter from the U.S. FDA for the Company's Tarapur, Maharashtra (India) facility. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 22/09/22 15:10 | Company Update | |
| | Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w. | |
| |
| | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate | 22/09/22 12:51 | | |
| | Intimation of Loss of Share Certificate by Shareholders. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 13/09/22 13:00 | Company Update | |
| | Lupin Receives Health Canada Approval for Rymti® (biosimilar Etanercept). | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 09/09/22 10:57 | Company Update | |
| | Lupin Launches Generic Suprep® Bowel Prep Kit in the United States. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 26/08/22 14:48 | Company Update | |
| | Lupin Launches Desvenlafaxine Extended-Release Tablets in the United States. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 26/08/22 12:04 | Company Update | |
| | Lupin Announces UK MHRA Approval of Lutio® (Tiotropium bromide inhalation powder) for Treatment of COPD. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 25/08/22 11:30 | Company Update | |
| | Lupin and I'rom Enter into an Exclusive Licensing Agreement for Denosumab biosimilar for Japan. | |
| |
| | Announcement under Regulation 30 (LODR)-Acquisition | 24/08/22 22:38 | Company Update | |
| | Lupin Limited has entered into Deed of Assignment with Boehringer Ingelheim International GmbH for the acquisition of brands Ondero and Ondero - Met (including trademark rights associated with the brands). | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 24/08/22 15:11 | Company Update | |
| | Lupin Receives Approval from U.S. FDA for Formoterol Fumarate Inhalation Solution. | |
| |
| | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | 24/08/22 12:22 | Company Update | |
| | Disclosure pursuant to Allotment of 30113 shares under ESOP. | |
| |
| | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate | 22/08/22 15:13 | | |
| | Intimation regarding Loss of Share Certificate by Shareholders. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 18/08/22 13:05 | Company Update | |
| | Lupin Receives Approval from U.S. FDA for Rufinamide Tablets USP. | |
| |
| | Business Responsibility and Sustainability Reporting (BRSR) | 16/08/22 19:06 | | |
| | Business Responsibility & Sustainability Report for the year ended March 31, 2022. | |
| |
| | Announcement under Regulation 30 (LODR)-Press Release / Media Release | 12/08/22 14:33 | Company Update | |
| | Lupin Receives Approval from U.S. FDA for Meclizine Hydrochloride Tablets USP. | |
| |
| | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate | 10/08/22 16:18 | | |
| | Intimation regarding issuance Duplicate share certificate. | |
| |
| | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate | 09/08/22 16:48 | | |
| | Intimation regarding loss of Share certificate by shareholder. | |
| |
| | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | 09/08/22 15:13 | Company Update | |
| | Transcript of the Q1 FY2023 Earnings Conference Call held on Thursday, August 4, 2022. | |
| |
| | Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015) | 05/08/22 10:06 | AGM/EGM | |
| | Lupin Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here | |
| |
| | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | 04/08/22 22:49 | Company Update | |
| | Audio/Video recording of the Earnings Call - Q1 FY 2023. | |
| |
| | Shareholder Meeting / Postal Ballot-Scrutinizer''s Report | 04/08/22 18:56 | AGM/EGM | |
| | Scrutinizer''s Report for declaration of voting results at the Fortieth Annual General Meeting of the Company, held on
Wednesday, August 3, 2022, at 4.00 p.m. (IST) through Video Conferencing/Other Audio Visual Means. | |
| |
| | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate | 04/08/22 16:51 | | |
| | Disclosure pursuant to Loss of Share Certificate by Shareholders. | |
| |
| | Announcement under Regulation 30 (LODR)-Investor Presentation | 04/08/22 16:35 | Company Update | |
| | Investor Presentation Q1 FY23 | |
| |